Navigation Links
CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial
Date:1/8/2009

LAS VEGAS, Jan. 8 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are University of California Medical Center San Diego, CA and Holy Cross Hospital, Fort Lauderdale, FL.

Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial. They treated their first patient in support of the trial in mid November 2008.

CVBT now has five sites that are open for enrollment and intends to announce additional sites as they open for screening patents.

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com.

     Media Contact:
     Allison Caplan,
     CardioVascular BioTherapeutics, Inc.
     (702) 839-7200, acaplan@cvbt.com

     Investor Contact:
     Amy Montano Gordon,
     CardioVascular BioTherapeutics, Inc.
     (702) 839-7220, inv
'/>"/>
SOURCE  CardioVascular BioTherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 

Related medicine news :

1. Packard Childrens Opens West Coasts Most Advanced Pediatric Surgery Center
2. MAQUET opens North Americas first VARIOP prefabricated operating suite system
3. MAQUET Opens North Americas First VARIOP Prefabricated Operating Suite System, Allowing Space Reconfiguration in Hours, Less Disruption Than Traditional Construction
4. Silverman, McDonald & Friedman Opens New Office in New Castle to Serve Legal Needs of Delaware Families
5. Leventhal Consulting Opens for Business
6. HealthCare Partners Opens a New Medical Office in Monrovia, CA
7. Cooper Opens Doors to New Era in Healthcare
8. Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC
9. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
10. Urgent Care Provider NextCare Opens Nine New Immediate Care Clinic Locations
11. Drug Information Association (DIA) Opens New Office In China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009).... 27 Preventing disease...tunately every year, new vaccines are being added ...es boost immunity for the same period of time? And...ed to keep immunity strong? ,, In this month,... Academy of Pediatrics, Michael Pichichero MD, Dir...
(Date:11/27/2009)...re Holdings has announced that it has become a nat...the largest nonprofit organizations dedicated to a... Delray Beach, FL (Vocus) N...: XCHO), a company specializing in the marketing a...ucts, has announced today that is has become a nat...
(Date:11/27/2009)...TLE, Nov. 27 Allrecipes.com , t...ksgiving traffic numbers, with more than 2.8 milli... a clear picture of what was served on the biggest...g meal in 2009 weighed in at 2,225 calories per se.... According to the Allrecipes site, Sweet Potato ...
(Date:11/27/2009)...list manufacturers who use medical load cells at t...dollars by bringing in technology partner Flintec ... pro-active medical manufacturers are calling in F...heir projects, ensuring that progress will not be ...ially outdated technology. , ...
(Date:11/26/2009)...ov. 27 The diabetes population in ... 25 years and annual medical spending on the disea...billion today, according to a study published in t...l Changing Diabetes ® Program (NCDP), a prog...a team from the University of Chicago. ,, Accor...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
... study of patients, doctors and family members sug...lls. When someone has a terminal illness, they may...dical procedures in a 'living will'. For example t...e death, may wish every possible measure to be tak...
...ew research from Albert Einstein College of Medic...ol that may help them predict who will develop a f... Albert Einstein College of Medicine finds the pre...a. Gait disorders are increasingly common wit...
... latest study researchers have observed that docto...blood pressure and other cardiac risk factors in e...pital, Georgia have carried out a population surve...gin have the lowest risk of heart disease, and the...
...esearchers in a study working with animals say the...rning. Although the research is early, they say it...ory and learning disorders. Researchers say previo...memory formation. They say this study provides a d...
...he latest study researchers proposed that large do...treatment for prostate cancer. Researchers say ten...minister vitamins and minerals,// and use untested...ng their health but inadvertently endanger their h...
...ve built a new model of the airway, which shows an...cations. In sleep apnoea, the upper airway tends t...the free flow of air.// This actually causes breat...prone to sleep apnoea than women and researchers i...
Other Medicine News:
(Date:11/26/2009)...SBURG, South Africa, Nov. 26 The 2...he Year Award in the Generic Pharmaceutical Market.... ,, (Logo: http://www.newscom.com/cgi-bin/prn...ear Award, the following criteria were used to ben...etitors: growth strategy and implementation, degre...
(Date:11/25/2009)... Mass., Nov. 25 Hologic,... leading developer, manufacturer and supplier of p...rgical products dedicated to serving the healthcar...he Radiological Society of North America (RSNA) at...ecember 3, 2009 to highlight our new SecurView(...
(Date:11/25/2009)..., Nov. 25 BioTrends Research Group...: Stelara report, the first in a multi-phase s...nch of Centocor Ortho-Biotech,s Stelara, from prod...ility. Each wave of the report provides quantitat...qualitative information from a subset of 20. The ...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea 4976 1Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea 4976 2West to Present at Two Upcoming Investor Conferences 56960 1West to Present at Two Upcoming Investor Conferences 56960 2FDA Clears a Test for Ovarian Cancer 4972 1FDA Clears a Test for Ovarian Cancer 4972 2
... 2007 APA Meeting -, COLLEGEVILLE, Pa., May 21, 20...udies examining safety and efficacy of,desvenlafax...,inhibitor (SNRI) being studied as a potential tre...MDD), were presented today at the,2007 American Ps...,Calif., by Wyeth Pharmaceuticals, a division of W...
...ong-term Response at Stable Doses, According to,Ne...ATLANTA, May 22, 2007 /PRNewswire/ -- UCB announce...se Week 2007 (DDW),demonstrated long-term response... with Cimzia (certolizumab pegol), the only Fc-fre...called PRECiSE 3 (P3), is a long-term open label,c...
Other Medicine Technology:New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8UCB Presents Long-Term CImzia Data in Crohn's Disease 2UCB Presents Long-Term CImzia Data in Crohn's Disease 3UCB Presents Long-Term CImzia Data in Crohn's Disease 4UCB Presents Long-Term CImzia Data in Crohn's Disease 5
IEC CL30 Centrifuge
HIV 1 /2 STAT-PAK Assay
REAL-Time Continuous Glucose Monitoring
Platelet Aggregation Profiler Model PAP-8E
Medicine Products: